Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system and PROTAC drugs, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas.
Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
May 2020. Progenra has received new funding for its Michael J. Fox Foundation Therapeutic Pipeline Award, Discovery and Development of Novel Parkin Activators. Progenra’s novel Parkin activator molecules are undergoing preclinical development, and this funding will...